COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 7.16M | 3.57M | 6.22M | 6.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 7.16M | 3.57M | 6.22M | 6.75M |
| Cost of Revenue | -- | 6.72M | 1.81M | 5.80M | 6.04M |
| Gross Profit | -- | 443.00K | 1.76M | 421.00K | 705.00K |
| SG&A Expenses | -- | 1.82M | 3.19M | -7.00K | 3.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 6.23M | 13.38M | 2.64M | 5.80M |
| Operating Income | -- | 935.00K | -9.80M | 3.58M | 951.00K |
| Income Before Tax | -- | -1.31M | -12.69M | -506.00K | 944.00K |
| Income Tax Expenses | -- | -1.77M | -647.00K | -1.53M | -1.20M |
| Earnings from Continuing Operations | -- | 0.46 | -12.04 | 1.03 | 2.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | 464.00K | -12.04M | 1.03M | 2.14M |
| EBIT | -- | 935.00K | -9.80M | 3.58M | 951.00K |
| EBITDA | -- | 2.74M | -9.04M | 5.37M | 2.74M |
| EPS Basic | -- | -2.83 | -9.28 | -2.66 | -2.05 |
| Normalized Basic EPS | -- | -0.81 | -4.92 | -0.65 | -1.54 |
| EPS Diluted | -- | -2.83 | -9.28 | -2.66 | -2.05 |
| Normalized Diluted EPS | -- | -0.81 | -4.92 | -0.65 | -1.54 |
| Average Basic Shares Outstanding | -- | 9.03M | 6.12M | 8.65M | 8.65M |
| Average Diluted Shares Outstanding | -- | 9.03M | 6.12M | 8.65M | 8.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |